Skip to main content

Table 4 Multivariate analysis of the predictive value of cumulative smoking dose on survival outcomes in patients with EGFR mutation receiving EGFR-TKIs

From: Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study

variable category PFS to EGFR-TKI p-value OS 95% CI p-value
HR 95% CI HR
Smoking history ever- smokers vs never smoker 1.89 1.27–2.81 0.002 1.52 0.87–2.64 0.13
Smoking dosage never smoker 1.00    1.00   
≤10 PY 0.81 0.43–1.50 0.49 0.83 0.32–2.14 0.68
11~ 30 PY 4.00 1.95–8.23 < 0.001 1.52 0.79–2.96 0.21
>  30 PY 16.2 6.37–61.6 < 0.001 3.98 1.84–8.28 < 0.001
  1. Adjusted by Age, PS, Sex, clinical stage and time of targeted therapy
  2. Abbreviations: PFS progression-free survival, OS overall survival, Ref. reference, EGFR epidermal growth factor receptor, TKI tyrosine kinase inhibitor, PS performance status, HR hazard ratio, 95% CI 95% confidence interval, PY pack-years